

## Global ADME Toxicology Testing Market Share & Size, Growth, Industry Trends | Emergen Research

The market of ADME toxicology testing is critical to evaluating the safety and efficiency of new drug candidates before they are allowed

VANCOUVER, BRITISH COLUMBIA, CANADA, January 16, 2025
/EINPresswire.com/ -- The global ADME Toxicology Testing Market is projected to grow significantly, expanding from an estimated USD 6.3 billion in 2024 to USD 10.8 billion by 2033, at a compound annual growth rate (CAGR) of 6.2%. This growth is driven by



increasing drug discovery and development activities, stringent regulatory requirements for drug safety, and advancements in in vitro and in silico testing technologies.

ADME toxicology testing evaluates the absorption, distribution, metabolism, and excretion (ADME) properties of chemical compounds, along with their toxicological effects. These assessments are critical in the pharmaceutical and biotechnology sectors to ensure drug safety and efficacy, minimize late-stage clinical failures, and reduce development costs.

Get Free Sample PDF Copy Of This Report@ <a href="https://www.emergenresearch.com/request-sample/3162">https://www.emergenresearch.com/request-sample/3162</a>

## Market Drivers

The rise in drug discovery and development activities, driven by the increasing prevalence of chronic diseases and demand for innovative therapeutics, is a key factor propelling market growth. Pharmaceutical companies are investing heavily in preclinical and clinical research to enhance drug safety and meet regulatory requirements.

Technological advancements in ADME toxicology testing, such as high-throughput screening

(HTS), 3D cell culture, and in silico modeling, are significantly improving the accuracy and efficiency of toxicity evaluations. These innovations are helping researchers predict drug safety profiles more effectively, reducing the risk of adverse events during clinical trials.

Government and regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), are emphasizing the need for comprehensive ADME toxicology testing to improve patient safety.

Browse Full Report: <a href="https://www.emergenresearch.com/industry-report/adme-toxicology-testing-market">https://www.emergenresearch.com/industry-report/adme-toxicology-testing-market</a>

## Market Challenges

The high cost of advanced testing technologies and equipment remains a significant challenge. Small and medium-sized enterprises (SMEs) often struggle to afford these tools, limiting their ability to conduct extensive preclinical testing.

Additionally, limited standardization in testing protocols across regions creates inconsistencies in data interpretation and compliance, posing barriers to market growth.

## Segment Insights

In Vitro Testing dominates the market, driven by its ability to provide rapid and cost-effective toxicity data without the ethical concerns associated with animal testing. In Silico Testing is the fastest-growing segment, fueled by advancements in computational modeling and predictive toxicology tools that enhance the efficiency of drug development. Industry Updates

In March 2023, Thermo Fisher Scientific launched a new high-throughput ADME platform to accelerate preclinical drug discovery and development workflows. In June 2022, Charles River Laboratories announced a strategic collaboration with a leading biotechnology company to enhance its ADME toxicology testing services using Al-driven

predictive models.

Request For Discount: <a href="https://www.emergenresearch.com/request-discount/3162">https://www.emergenresearch.com/request-discount/3162</a>

**Key Players** 

Prominent companies in the global ADME toxicology testing market include:

Thermo Fisher Scientific Inc.
Charles River Laboratories International, Inc.
Eurofins Scientific

PerkinElmer, Inc.

Covance Inc.

Agilent Technologies, Inc.

Bio-Rad Laboratories, Inc.

**Promega Corporation** 

Cyprotex Limited

Cellular Dynamics International

**Market Segmentation** 

By Technology (Revenue, USD Million; 2020-2033):

In Vitro Testing
Cell-Based Assays
Biochemical Assays
Others
In Silico Testing
In Vivo Testing

By Application (Revenue, USD Million; 2020-2033):

Systemic Toxicity Testing Renal Toxicity Testing Hepatotoxicity Testing Neurotoxicity Testing Others

By End-user (Revenue, USD Million; 2020-2033):

Pharmaceutical and Biotechnology Companies Academic and Research Institutions Contract Research Organizations (CROs)

By Regional Outlook (Revenue, USD Million; 2020-2033):

North America

**United States** 

Canada

Europe

**United Kingdom** 

Germany

France

Rest of Europe

Asia-Pacific

China
Japan
India
Rest of Asia-Pacific
Latin America
Brazil
Rest of Latin America
Middle East and Africa
South Africa

Buy Now: https://www.emergenresearch.com/select-license/3162

Eric Lee Emergen Research + +91 90210 91709 sales@emergenresearch.com Visit us on social media:

Facebook

Χ

UAE

Rest of MEA

LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/777553887

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.